Indobufen Versus Aspirin in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Authors:
- Ahmad HassanAHAhmad Hassan
- Muhammad Rayyan YousafiMYMuhammad Rayyan Yousafi
- Muhammad EssaMEMuhammad Essa
- Affaf MahmoodAMAffaf Mahmood
- Ahmed AsifAAAhmed Asif
- Muhammad SarmadMSMuhammad Sarmad
- Usama AhmadUAUsama Ahmad
- Amna ImanAIAmna Iman
- Semil SaleemSSSemil Saleem
- Kanza RaeesKRKanza Raees
- Maria SreenaMSMaria Sreena
- Ubaid Ur RehmanURUbaid Ur Rehman
- 28 October 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Abstract
Background: Acute ischemic stroke (AIS) is a major cause of death and disability worldwide. Early antiplatelet therapy reduces recurrence and improves outcomes. Although aspirin is standard treatment, its use is limited by bleeding risk. Indobufen, a reversible cyclooxygenase inhibitor with shorter platelet inhibition, may offer a safer alternative. Objective: To compare the efficacy and safety of indobufen versus aspirin in patients with AIS. Methods: A systematic review and meta-analysis was performed according to PRISMA guidelines. PubMed, Embase, Cochrane Library, and ScienceDirect were searched through February 2026 for randomized controlled trials comparing indobufen with aspirin in adults with AIS. Primary outcomes were functional outcomes (modified Rankin Scale), neurological improvement (NIHSS) at 90 days, recurrent ischemic stroke at 90 days, and composite vascular events. Secondary outcomes included bleeding and other adverse events. Pooled estimates were calculated using fixed- or random-effects models based on heterogeneity. The risk of bias was assessed using Cochrane RoB 2.0. Results: Four randomized controlled trials (278 records screened) were included. Indobufen showed no significant difference versus aspirin in NIHSS improvement at 90 days (MD: 0.01, 95% CI: −0.07 to 0.09) or recurrent ischemic stroke (OR: 0.54, 95% CI: 0.05-5.61). However, indobufen significantly improved modified Rankin Scale outcomes (MD: −1.11, 95% CI: −1.32 to −0.90) and reduced moderate-to-severe bleeding at 3 months (OR: 0.57, 95% CI: 0.35-0.92). Conclusions: Indobufen provides efficacy comparable to aspirin, with better functional outcomes and lower short-term bleeding risk, supporting its potential as an alternative antiplatelet therapy in AIS. Larger, international, multicenter trials are warranted. Larger, high-quality, multicenter international trials are warranted to confirm these findings.Keywords
This publication has 20 references indexed in Scilit:
- The effect of indobufen and aspirin on platelet function in acute ischemic stroke patients with early neurological deteriorationEuropean Journal of Pharmacology, 2025
- Indobufen versus aspirin in patients with indication for antiplatelet therapy: A systematic review and meta-analysisVascular Pharmacology, 2025
- Acute Ischemic Stroke in the Clinic and the Laboratory: Targets for Translational ResearchNeuroscience, 2024
- Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trialThe Lancet Neurology, 2023
- Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attackMedicine, 2021
- Intracranial Hemorrhage During Dual Antiplatelet TherapyJACC, 2021
- Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIANew England Journal of Medicine, 2018
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2013
- Anti‐platelet therapy: cyclo‐oxygenase inhibition and the use of aspirin with particular regard to dual anti‐platelet therapyBritish Journal of Clinical Pharmacology, 2011
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996